Recent advances in the development of telomerase inhibitors for the treatment of cancer

Bibliography

• AMERICAN CANCER SOCIETY: American Cancer SocietyStatistics (1998).
   Google Scholar
• GREIDER CW, BLACKBURN EH: Identification of aspecific telomere terminal transferase activity in Tetrahymena extracts. Cell (1985) 43:405–413.
   PubMed Web of Science ®Google Scholar
• MORIN GB: The human telomere terminal transferase enzyme is a ribonucleoprotein that synthesises TTAGGG repeats. Cell (1989) 59:521–529.
   PubMed Web of Science ®Google Scholar
• GREIDER CW: Telomere length regulation. Ann. Rev. Biochem. (1996) 65:337–365.
   PubMed Web of Science ®Google Scholar
• MEYNE J, RATLIFF RL, MOYZIS RK: Conservation of thehuman telomere sequence (TTAGGG), among vertebrates. Proc. Natl. Acad. Sci. USA (1 98 9) 86:7049-7053.
   Google Scholar
• BLACKBURN EH: Structure and function of telomeres.Nature (1991) 350:569–573.
   PubMed Web of Science ®Google Scholar
• LANSDORP PM, VERWOERD NP, VAN DE, RIJKE FM et al.: Heterogeneity in telomere length of human chromo-somes. Hum. Mol Genet. (1996) 5:685–691.
   PubMed Web of Science ®Google Scholar
• WATSON JD: Origin of concatomeric T7 DNA. Nature New Biol (1972) 239:197–201.
   PubMedGoogle Scholar
• OLOVNIKOV AM: A theory of marginotomy. J. Theor. Biol. (1973) 41:181–190.
   PubMed Web of Science ®Google Scholar
• MCCLINTOCK B: The stability of broken ends ofchromosomes in Zea Mays. Genetics (1941) 26:234–282.
   PubMedGoogle Scholar
• VAN STEENSEL B, SMOGORZEWSKA A, DE LANGE T: TRF2 protects human telomeres from end-to-end fusions. Cell (1998) 92:401–413.
   PubMed Web of Science ®Google Scholar
• KRUK PA, RAMPINO NJ, BOHR VA: DNA damage andrepair in telomeres: relation to ageing. Proc. Natl. Acad. ScL USA (1995) 92:258–262.
   PubMed Web of Science ®Google Scholar
• HARLEY CB, FUTCHER AB, GREIDER CW: Telomeres shorten during ageing of human fibroblasts. Nature (1990) 345:458–460.
   PubMed Web of Science ®Google Scholar
• ALLSOPP RC, HARLEY CB: Evidence for a criticaltelomere length in senescent human fibroblasts. Exp. Cell Res. (1995) 219:130–136.
   PubMed Web of Science ®Google Scholar
• WRIGHT WE, TESMER VM, HUFFMAN KE, LEVENE SD, SHAY JW: Normal human chromosomes have long G-rich telomeric overhangs at one end. Genes Dev. (1997) 11:2801–2809.
   PubMed Web of Science ®Google Scholar
• NAKAMURA TM, MORIN GB, CHAPMAN KB et al.: Telomerase catalytic subunit homologs from fission yeast and human. Science (1997) 277:955–959.
   PubMed Web of Science ®Google Scholar
• •One of a number of independent studies identifying the human telomerase catalytic subunit hTERT. See also references [17–19].
   Google Scholar
• MEYERSON M, COUNTER CM, EATON EN et al.: hEST2,the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortaliza-tion. Cell (1997) 90:785–795.
   PubMed Web of Science ®Google Scholar
• HARRINGTON L, ZHOU W, MCPHAIL T et al.: Humantelomerase contains evolutionarily conserved catalytic and structural subunits. Genes Dev. (1997) 11:3109–3115.
   PubMed Web of Science ®Google Scholar
• KILIAN A, BOWTELL DD, ABUD HE et al.: Isolation of a candidate human telomerase catalytic subunit gene, which reveals complex splicing patterns in different cell types. Hum. Mol. Genet. (1997) 6:2011–2019.
   PubMed Web of Science ®Google Scholar
• FENG J, FUNK W, WANG S-S et al.: The RNA component of human telomerase. Science (1995) 269:1236–1241.
   PubMed Web of Science ®Google Scholar
• ••A significant study describing the cloning of the RNAcomponent of human telomerase and effects of antisense hTR expression on HeLa cells. This study enabled the rational design of antisense oligonucleotides targeted against telomerase thus allowing a greater understanding of the role telomerase plays in cellular proliferation.
   Google Scholar
• HARRINGTON L, MCPHAIL T, MAR V et al.: A mammalian telomerase-associated protein. Science (19 9 7) 275:973–977.
   Google Scholar
• NAKAYAMA J-I, SAITO M, NAKAMURA H, MATSUURA A, ISHIKAWA F: TLP1: A gene encoding a protein component of mammalian telomerase is a novel member of WD repeats family. Cell (1997) 88:875–884.
   PubMed Web of Science ®Google Scholar
• KIM NW, PIATYSZEK MA, PROWSE KR et al.: Specific association of human telomerase activity with immortal cells and cancer. Science (1 9 9 4) 266:2011-2015.
   Google Scholar
• ••Study describing the TRAP assay protocol, which has nowbecome a near-universal standard method for determining telomerase activity.
   Google Scholar
• COUNTER CM, HIRTE HW, BACCHETTI S, HARLEY CB: Telomerase activity in human ovarian carcinoma. Proc. Natl. Acad. ScL USA (1994) 91:2900–2904.
   PubMed Web of Science ®Google Scholar
• SOMMERFELD HJ, MEEKER AK, PIATYSZEK MA, BOVA GS,SHAY JW, COFFEY DS: Telomerase activity: a prevalent marker of malignant human prostate tissue. Cancer Res. (1996) 56:218–222.
   PubMed Web of Science ®Google Scholar
• TATEMATSU K, NAKAYAMA J, DANBARA M et al.: A novelquantitative 'stretch PCR assay' that detects a dramatic increase in telomerase activity during the progression of myeloid leukemias. Oncogene (1996) 13:2265–2274.
   PubMed Web of Science ®Google Scholar
• LANDBERG G, NIELSEN NH, NILSSON P, EMDIN SO, CAJANDER J, ROOS G: Telomerase activity is associated with cell cycle deregulation in human breast cancer. Cancer Res. (1997) 57:549–554.
   PubMed Web of Science ®Google Scholar
• AVILION AA, PIATYSZEK MA, GUPTA, J, SHAY JW, BACCHETTI S, GREIDER CW: Human telomerase RNA and telomerase activity in immortal cell lines and tumor tissues. Cancer Res. (1996) 56:645–650.
   PubMed Web of Science ®Google Scholar
• TAKAKURA M, KYO S, KANAYA T et al: Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcription activa-tion in immortalized and cancer cells. Cancer Res. (1999) 59:551–557.
   PubMed Web of Science ®Google Scholar
• HORIKAWA I, CABLE PL, AFSHARI C, BARRETT JC: Cloning and characterization of the promoter region of human telomerase reverse transcriptase gene. Cancer Res. (1999) 59:826–830.
   PubMed Web of Science ®Google Scholar
• MORIN GB: Is telomerase a universal cancer target? J. Natl. Cancer Inst. (1995) 87:859–861.
   Google Scholar
• HAMILTON SE, COREY DR: Telomerase: anti-cancer target or just a fascinating enzyme? Chem. Biol. (1996) 3:863–867.
   Google Scholar
• RAYMOND E, SUN D, CHEN S-F, WINDLE B, VON HOFF DD: Agents that target telomerase and telomeres. Curr. Opin. Biotech. (1996) 7:583–591.
   PubMed Web of Science ®Google Scholar
• PERRY PJ, KELLAND LR: Telomeres and telomerase: targets for cancer chemotherapy? Exp. Opin. Ther. Patents (1998) 8:1567–1586.
   Web of Science ®Google Scholar
• •The most thorough review of telomerase inhibitors to date detailing compounds described in both the scientific and patent literature.
   Google Scholar
• PITTS AE, COREY DR: The telomerase challenge - an unusual problem in drug discovery. Drug Disc. Today (1999) 4:155–161.
   PubMed Web of Science ®Google Scholar
• BLASCO MA, LEE H-W, HANDE MP et al.: Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell (1997) 91:25–34.
   PubMed Web of Science ®Google Scholar
• LEE H-W, BLASCO MA, GOTTLIEB GJ, HORNER JW II, GREIDER CW, DEPINHO RA: Essential role of mouse telomerase in highly proliferative organs. Nature (1998) 392:569–574.
   PubMed Web of Science ®Google Scholar
• •Study revealing the phenotype of mice lacking telomerase RNA and an essential role for telomerase in the long-term viability of high renewal organ systems. See also reference [38].
   Google Scholar
• NIIDA H, MATSUMOTO T, SATOH H et al.: Severe growth defect in mouse cells lacking the telomerase RNA component. Nature Genet. (1998) 19:203–206.
   PubMed Web of Science ®Google Scholar
• RUDOLPH KL, CHANG S, LEE H-W et al.: Longevity, stress response and cancer in aging telomerase-deficient mice. Cell (1999) 96:701–712.
   PubMed Web of Science ®Google Scholar
• BODNAR AG, OUELLETTE M, FROLKIS M et al.: Extension of life-span by introduction of telomerase into normal human cells. Science (1998) 279:349–352.
   PubMed Web of Science ®Google Scholar
• ••Key study probing the roles of hTERT expression andtelomere length in cellular senescence.
   Google Scholar
• VAZIRI H, BENCHIMOL S: Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span. Curr. Biol. (1998) 8:279–282.
   PubMed Web of Science ®Google Scholar
• JIANG XR, JIMENEZ G, CHANG E et al. Telomerase expression in human somatic cells does not induce changes associated with a transformed phenotype. Nature Genet. (1999) 21:111–114.
   PubMed Web of Science ®Google Scholar
• MORALES CP, HOLT SE, OUELLETTE M et al.: Absence of cancer-associated changes in human fibroblasts immortalized with telomerase. Nature Genet. (1999) 21:115–118.
   PubMed Web of Science ®Google Scholar
• COUNTER CM, HAHN WC, WEI W et al.: Dissociation among in vitro telomerase activity, telomere mainte-nance, and cellular immortalization. Proc. Natl. Acad. Sci. USA (1998) 95:14723–14728.
   PubMed Web of Science ®Google Scholar
• ••Seminal study (together with references [45,46]) thatdemonstrates a bypass of cellular crisis through ectopic expression of hTERT in virally transformed cells.
   Google Scholar
• ZHU J, WANG H, BISHOP JM, BLACKBURN EH: Telomerase extends the lifespan of virus-transformed human cells without net telomere lengthening. Proc. Natl. Acad. Sci. USA (1999) 96:3723–3728.
   PubMed Web of Science ®Google Scholar
• HALVORSEN TL, LEIBOWITZ G, LEVINE F: Telomerase activity is sufficient to allow transformed cells to escape from crisis. Mol Cell Biol. (1999) 19:1864–1870.
   PubMed Web of Science ®Google Scholar
• HAHN WC, COUNTER CM, LUNDBERG AS, BEIJERS-BERGEN RL, BROOKS MW, WEINBERG RA: Creation of human tumour cells with defined genetic elements. Nature (1999) 400:464–468.
   PubMed Web of Science ®Google Scholar
• ••This paper describes the tumourigenic transformation ofnormal cells following ectopic expression of hTERT in combination with large-T and Ras.
   Google Scholar
• ZIJLMANS JM, MARTENS UM, POON S et al.: Telomeres in the mouse have large inter-chromosomal variations in the number of T2AG3 repeats. Proc. Natl. Acad. Sci. USA (1997) 94:7423–7428.
   PubMed Web of Science ®Google Scholar
• MARTENS UM, ZIJLMANS JM, POON S et al.: Shorttelomeres on human chromosome 17p. Nature Genet. (1998) 18:76–80.
   PubMed Web of Science ®Google Scholar
• HANDE MP, SAMPER E, LANSDORP P, BLASCO MA: Telomere length dynamics and chromosomal instability in cells derived from telomerase null mice. J. Cell Biol. (1999) 144:589–601.
   PubMed Web of Science ®Google Scholar
• SHARMA S, RAYMOND E, SODA H et al.: Preclinical and clinical strategies for development of telomerase and telomere inhibitors. Annal Oncol. (1997) 8:1063–1074.
   PubMed Web of Science ®Google Scholar
• LO YMD: Quantitative assays for telomerase: means for studying the end. Clin. Chem. (1998) 44:2399–2400.
   PubMed Web of Science ®Google Scholar
• BRESLOW RA, SHAY JW, GAZDAR AF, SRIVASTAVA S: Telomerase and early detection of cancer: a National Cancer Institute workshop. J. Natl. Cancer Inst. (1997) 89:618–623.
   PubMed Web of Science ®Google Scholar
• MURRAY GI, TAYLOR MC, MCFADYEN MC et al.: Tumor-specific expression of cytochrome P450 CYP1B1. Cancer Res. (1997) 57:3026–3031.
   PubMed Web of Science ®Google Scholar
• RAMAKRISNAN S, EPPENBERGER U, MUELLER H, SHINKAIY, NARAYANAN R: Expression profile of the putative catalytic subunit of the telomerase gene. Cancer Res. (1998) 58:622–625.
   PubMed Web of Science ®Google Scholar
• HIYAMA E, HIYAMA K, YOKOYAMA T, MATSUURA Y, PIATYSZEK MA, SHAY JW: Correlating telomerase activity levels with human neuroblastoma outcomes. Nature Med. (1995) 1:249–255.
   PubMed Web of Science ®Google Scholar
• CLARK GM, OSBORNE CK, LEVITT D, WU F, KIM NW: Telomerase activity and survival of patients with node-positive breast cancer. J. Natl. Cancer Inst. (1997) 89:1874–1881.
   PubMed Web of Science ®Google Scholar
• FARAONI I, TURRIZIANI M, MASCI G et al: Decline intelomerase activity as a measure of tumor cell killing by antineoplastic agents in vitro. Clin. Cancer Res. (1997) 3:579–585.
   PubMed Web of Science ®Google Scholar
• TAKIYAMA I, TERASHIMA M, UESUGI N et al: Telomeraseactivity is a good predictor for response to chemotherapy. Proc. Amer. Assoc. Cancer Res. (1998) 39:4128.
   Google Scholar
• BURGER AM, DOUBLE JA, NEWELL DR: Inhibition of telomerase activity by cisplatin in human testicular cancer cells. Eur. J. Cancer (1997) 33:638–644.
   PubMed Web of Science ®Google Scholar
• ISHIBASHI T, LIPPARD SJ: Telomere loss in cells treatedwith cisplatin. Proc. Nad Acad. Sci. USA (1998) 95:4219–4223.
   PubMed Web of Science ®Google Scholar
• ALDOUS WK, MAREAN AJ, DEHART MJ, MATEJ LA, MOORE KH: Effects of tamoxifen on telomerase activity in breast carcinoma cell lines. Cancer (1999) 85:1523–1529.
   PubMed Web of Science ®Google Scholar
• OGINO M, HISATOMI H, HANAZONO M: Effectiveness ofindomethacin as an antitumor agent in colon 26-bearing conventional and nude mice, and telomerase activity in the tumors. Exp. Anim. (1999) 48:15–21.
   PubMed Web of Science ®Google Scholar
• KONDO S, TANAKA Y, KONDO Y et al: Antisense telomerase treatment: induction of two distinct pathways, apoptosis and differentiation. FASEB J. (1998) 12:801–811.
   PubMed Web of Science ®Google Scholar
• KONDO Y, KONDO S, TANAKA Y, HAQQI T, BARNA BP,COWELL JK: Inhibition of telomerase increases the susceptibility of human malignant glioblastoma cells to cisplatin-induced apoptosis. Oncogene (1998) 16:2243–2248.
   PubMed Web of Science ®Google Scholar
• YAMAGUCHI F, MORRISON RS, TAKAHASHI H, TERAMOTO A: Anti-telomerase therapy suppressed glioma proliferation. Oncol Reports (1999) 6:773–776.
   PubMed Web of Science ®Google Scholar
• NAKA K, YOKOZAKI H, YASUI W, TAHARA H, TAHARA E, TAHARA E: Effect of antisense human telomerase RNA transfection on the growth of human cancer cell lines. Biochem. Biophys. Res. Commun. (1999) 255:753–758.
   PubMed Web of Science ®Google Scholar
• BISOFFI M, CHAKERIAN AE, FORE ML et al.: Inhibition of human telomerase by a retrovirus expressing telomeric antisense RNA. Eur. J. Cancer (1998) 34:1242–1249.
   PubMed Web of Science ®Google Scholar
• PITTS AE, COREY DR: Inhibition of human telomeraseby 2'-amethyl-RNA. Proc. Natl. Acad. ScL USA (1998) 95:11549–11554.
   PubMed Web of Science ®Google Scholar
• KANAZAWA Y, OHKAWA K, UEDA K et al.: Hammerheadribozyme-mediated inhibition of telomerase activity in extracts of human hepatocellular carcinoma cells. Biochem. Biophys. Res. Commun. (1996) 225:570–576.
   PubMed Web of Science ®Google Scholar
• YOKOYAMA Y, TAKAHASHI Y, SHINOHARA A: Attenua-tion of telomerase activity by a hammerhead ribozyme targeting the template region of telomerase RNA in endometrial carcinoma cells. Cancer Res. (1998) 58:5406–5410.
   PubMed Web of Science ®Google Scholar
• WAN MSK, FELL PL, AKHTAR S: Synthetic 2'-0-methyl--modified hammerhead ribozymes targeted to the RNA component of telomerase as sequence-specific inhibi-tors of telomerase activity. Antisense Nucleic Acid Drug Dev. (1998) 8:309–317.
   PubMedGoogle Scholar
• ZAFFARONI N, FOLINI M, COLELLA G, VILLA R, LUALDI S,DIADONE MG: Inhibition of telomerase activity by a hammerhead ribozyme in human melanoma cells. Proc. Amer. Assoc. Cancer Res. (1999) 40:3913.
   Google Scholar
• GLUKHOV Al, ZIMNIK OV, GORDEEV SA, SEVERIN SE: Inhibition of telomerase activity of melanoma cells in vitro by antisense oligonucleotides. Biochem. Biophys. Res. Commun. (1998) 248:368–371.
   PubMed Web of Science ®Google Scholar
• KONDO S, KONDO Y, LI G, SILVERMAN RH, COWELL JK: Targeted therapy of human malignant glioma in a mouse model by 2-5A antisense directed against telomerase RNA. Oncogene (1998) 16:3323–3330.
   PubMed Web of Science ®Google Scholar
• •A novel antisense-based approach toward telomerase RNA showing potent in vivo antitumour activity, and thereby providing further target validation.
   Google Scholar
• MATA JE, JOSHI SS, PALIN B et al.: A hexameric phosphorothioate oligonucleotide telomerase inhibitor arrests growth of Burkitt's lymphoma cells in vitro and in vivo. Toxicol. Appl. Pharm. (1997) 144:189–197.
   PubMed Web of Science ®Google Scholar
• OHNUMA T, LI F-L, HOLLAND JF: Inhibitory effects of telomere-mimic phosphorothioate oligonucleotides on various human tumor cells in vitro. AntiCancer Res. (1997) 17:2455–2458.
   PubMed Web of Science ®Google Scholar
• SAEKI T, TAKASHIMA S, KOGA M et al.: Inhibitory effect of telomere-mimic phosphorothioate oligodeoxynu-cleotides (S-ODNO on human tumor cell lines. Proc. Amer. Assoc. Cancer Res. (1998) 39:2398.
   Google Scholar
• DUNCAN VE, AJMANI PS, HUGHES JA: Cellular delivery is a major obstacle for oligodeoxynucleotide inhibi-tion of telomerase. AntiCancerRes. (1998) 18:4105–4108.
   PubMed Web of Science ®Google Scholar
• KATO H, ARAYA S, HIROSE K et al.: In vitro tumorgrowth inhibition by telomerase antisense and anticancer agents. Proc. Amer. Assoc. Cancer Res. (1998) 39:2833.
   Google Scholar
• CATAPANO CV, PACHECO D, CARBONE GMR, MCGUFFIEEM: Inhibition of human telomerase activity by foldback triplex-forming oligonucleotides (FTF0s). Proc. Amer. Assoc. Cancer Res. (1999) 40:134.
   Google Scholar
• CHIN AC, PIATYSZEK MA, WONG SSY et al.: Inhibition of human telomerase activity by antisense oligonucleo-tides. Proc. Amer. Assoc. Cancer Res. (1998) 39:3686.
   Google Scholar
• NORTON JC, PAITYSZEK MA, WRIGHT WE, SHAY JW, COREY DR: Inhibition of human telomerase activity by peptide nucleic acids. Nature Biotech. (1996) 14:615–619.
   PubMed Web of Science ®Google Scholar
• HAMILTON SE, PITTS AE, KATIPALLY RR et al. Identifica- tion of determinants for inhibitor binding within the
   Google Scholar
• •By using peptide nucleic acid scanning of the hTR template region, this study identifies specific interactions important for optimal oligonucleotide recognition and binding.
   Google Scholar
• ZAFFARONI N, VILLA R, FOLINI M, DAIDONE MG: In vitro inhibition of human melanoma telomerase by peptide nucleic acids (PNAs). Proc. Amer. Assoc. Cancer Res. (1998) 39:2078.
   Google Scholar
• HARRISON JG, FRIER C, LAURANT R, DENNIS R, RANEY KD, BALASUBRAMANIAN S: Inhibition of human telomerase by PNA-cationic peptide conjugates. Bioorg. Med. Chem. Lett. (1999) 9:1273–1278.
   PubMed Web of Science ®Google Scholar
• MATTHES E, LEHMANN C: Telomerase protein rather than its RNA is the target of phosphorothioate-modified oligonucleotides. Nucleic Acids Res. (1999) 27:1152–1158.
   PubMed Web of Science ®Google Scholar
• ITO H, KYO S, KANAYA T, TAKAKURA M, INOUE M, NAMIKI M: Expression of human telomerase subunits and correlation with telomerase activity in urothelial cancer. Clin. Cancer Res. (1998) 4:1603–1608.
   PubMed Web of Science ®Google Scholar
• TAKAKURA M, KYO S, KANAYA T, TANAKA M, INOUE M: Expression of human telomerase subunits and correlation with telomerase activity in cervical cancer. Cancer Res. (1998) 58:1558–1561.
   PubMed Web of Science ®Google Scholar
• WANG J, XIE LY, ALLAN S, BEACH D, HANNON GJ: Myc activates telomerase. Genes Dev. (1998) 12:1769–1774.
   PubMed Web of Science ®Google Scholar
• WU K-J, GRANDORI C, AMACKER M et al.: Direct activa-tion of TERT transcription by c-MYC. Nature Genet. (1999) 21:220–224.
   PubMed Web of Science ®Google Scholar
• GREENBERG RA, O'HAGAN RC, DENG H et al.: Telomerase reverse transcriptase gene is a direct target of c-Myc but is not functionally equivalent in cellular transformation. Oncogene (1999) 18:1219–1226.
   Google Scholar
• FUJIMOTO K, TAKAHASHI M: Telomerase activity in human leukemic cell lines is inhibited by antisense pentadecadeoxynucleotides targeted against c-myc mRNA. Biochem. Biophys. Res. Commun. (1997) 241:775–781.
   PubMed Web of Science ®Google Scholar
• AKHTAR S, AGRAWAL S: In vivo studies with antisense oligonucleotides. Trends Pharmacol Sci. (1997) 18:12–18.
   PubMed Web of Science ®Google Scholar
• OHMURA H, TAHARA H, SUZUKI M et al.: Restoration of the cellular senescence program and repression of telomerase by human chromosome 3. Jap. J. Cancer Res. (1995) 86:899–904.
   PubMedGoogle Scholar
• CUTHBERT AP, BOND J, TROTT DA et al: Telomerase repressor sequences on chromosome 3 and induction of permanent growth arrest in human breast cancer cell lines. J. Natl. Cancer Inst. (1999) 91:37–45.
   PubMed Web of Science ®Google Scholar
• •This paper provides insights into possible telomerase regulation pathways.
   Google Scholar
• HORIKAWA I, OSHIMURA M, BARRETT JC: Repression of telomerase catalytic subunit by a gene on human chromosome 3 that induces cellular senescence. Mol. Carcinogen. (1998) 22:65–72.
   PubMed Web of Science ®Google Scholar
• YANG X, HU Y-F, RUSSO IH, SLATER C, RUSSO J: Suppres-sion of transformed phenotypes in human breast epithelial cells by introduction of chromosome 17 is associated with repression of telomerase activity. Proc. Amer. Assoc. Cancer Res. (1999) 40:4854.
   Google Scholar
• STRAHL C, BLACKBURN EH: The effects of nucleosideanalogues on telomerase and telomeres in Tetrahy-mena. Nucleic Acids Res. (1994) 22:893–900.
   PubMed Web of Science ®Google Scholar
• STRAHL C, BLACKBURN EH: Effects of reverse transcrip-tase inhibitors on telomere length and telomerase activity in two immortalised human cell lines. Mol. Biol. (1996) 16:53–65.
   Web of Science ®Google Scholar
• •This study, together with [99], demonstrates that telomerase activity may be inhibited by established reverse transcrip-tase inhibitors.
   Google Scholar
• PAI RB, PAI B, KUKHANOVA M eta].: Telomerase from human leukemia cells: properties and its interaction with deoxynucleoside analogues. Cancer Res. (1998) 58:1909–1913.
   Google Scholar
• MELANA SM, HOLLAND JF, POGO BG-T: Inhibition of cell growth and telomerase activity of breast cancer cells in vitro by 3'-azido-3'deoxythymidine. Cancer Res. (1998) 4:693–696.
   Web of Science ®Google Scholar
• OLIVERO OA, POIRIER MC: Preferential incorporation of 3'-azido-2',3'-dideoxythymidine into telomeric DNA and Z-DNA-containing regions of Chinese hamster ovary cells. Mol Carcinog. (1993) 8:81–88.
   PubMed Web of Science ®Google Scholar
• GOMEZ DE, TEJERA AM, OLIVERO OA: Irreversible telomere shortening by 3'-azido-2',3'-dideoxythymi-dine (AZT) treatment. Biochem. Biophys. Res. Commun. (1998) 246:107–110.
   PubMed Web of Science ®Google Scholar
• MURAKAMI J, NAGAI N, SHIGEMASA K, OHAMA K: Inhibition of telomerase activity and cell proliferation by a reverse transcriptase inhibitor in gynaecological cancer cell lines. Eur. J. Cancer (1999) 35:1027–1034.
   PubMed Web of Science ®Google Scholar
• OLIVERO OA, ANDERSON LM, DIWAN BA et al.: Transpla-rental effects of 3'-azido-2',3'-dideoxythymidine (AZT): tumorigenicity in mice and genotoxicity in mice and monkeys. J. Natl. Cancer Inst. (1997) 89:1602–1608.
   PubMed Web of Science ®Google Scholar
• PERRY PJ, GOWAN SM, RESZKA AP et al.: 1,4- and 2,6-Disubstituted anthracene-9,10-dione derivatives as inhibitors of human telomerase. J. Merl. Chem. (1998) 41:3253–3260.
   PubMed Web of Science ®Google Scholar
• •This paper, together with [138], provides the first systematic study of telomerase inhibition by a series of structurally related non-nucleoside derivatives, providing valuable insight into structure-activity relationships.
   Google Scholar
• FLETCHER TM, SALAZAR M, CHEN S-F: Human telomerase inhibition by 7-deaza-2'-deoxypurine nucleoside triphosphates. Biochemistry (1996) 35:15611–15617.
   PubMed Web of Science ®Google Scholar
• BLACKBURN EH: Telomeres: no end in sight. Cell (1994) 77:621–623.
   PubMed Web of Science ®Google Scholar
• BLACKBURN EH, GREIDER CW: Telomeres. Cold Spring Harbor Press, New York (1995).
   Google Scholar
• HENDERSON E, HARDIN CC, WALK, SK, TINOCO, I, BLACKBURN, EH: Telomeric DNA oligonucleotides form novel intramolecular structures containing guanine-guanine base pairs. Cell (1987) 51:899–908.
   PubMed Web of Science ®Google Scholar
• WELLINGER RJ, SEND: The DNA structures at the ends of eukaryotic chromosomes. Eur. J. Cancer (1997) 33:735–749.
   PubMed Web of Science ®Google Scholar
• KANG CH, ZHANG XH, RATLIFF R, MOYZIS R, RICH A: Crystal structure of 4-stranded Oxytricha telomeric DNA. Nature (1992) 356:126–131.
   PubMed Web of Science ®Google Scholar
• WANG Y, PATEL DJ: Solution structure of the human telomeric repeat d[AG3(T2AG3)3] G-tetraplex. Structure (1993) 1:263–282.
   PubMed Web of Science ®Google Scholar
• ••NMR structure providing a well-defined basis for the designof ligands capable of inhibiting telomerase by preferentially interacting with the folded human telomeric DNA tetraplex.
   Google Scholar
• ABOULELA F, MURCHIE AIH, NORMAN DG, LILLEY DMJ: The solution structure of a parallel-stranded tetraplex formed by d(TG41) in the presence of Na + ions by NMR spectroscopy. J. Mol Biol. (1994) 243:458–471.
   PubMed Web of Science ®Google Scholar
• LAUGHLAN G, MURCHIE AIH, NORMAN, DG, MOORE MH, MOODY PCE, LILLEY DMJ, LUISI B: The high-resolution crystal structure of parallel-stranded guanine tetraplex. Science (1994) 265:520–524.
   PubMed Web of Science ®Google Scholar
• PHILLIPS K, DAUTER Z, MURCHIE AIH, LILLEY DMJ, LUISI B: The crystal structure of a parallel-stranded guanine tetraplex at 0.95 A resolution. J. Mol. Biol. (1997) 273:171–182.
   PubMed Web of Science ®Google Scholar
• •High-resolution structure useful for the design of novel ligands that can interact with intermolecular DNA tetraplexes.
   Google Scholar
• WILLIAMSON JR: G-quartet structures in telomeric DNA. Ann. Rev. Biophys. Biomol StrucL (1994) 23:703–730.
   PubMedGoogle Scholar
• FEIGON J, KOSHLAP KM, SMITH FW: 111 NMR spectros-copy of DNA triplexes and quadruplexes. Meth. Enzymol. (1995) 261:225–255.
   PubMed Web of Science ®Google Scholar
• RHODES D, GIRALDO R: Telomere structure and function. Curr. Opin. Struct. Biol (1995) 5:311–322.
   PubMed Web of Science ®Google Scholar
• SALAZAR M, THOMPSON BD, KERWIN SM, HURLEY LH: Thermally induced DNA-RNA hybrid to G-quadruplex transitions: possible implications for telomere synthesis by telomerase. Biochemistry (1996) 35:16110–16115.
   PubMed Web of Science ®Google Scholar
• VAN STEENSEL B, DE LANGE T: Control of telomere length by the human telomeric protein TRF1. Nature (1997) 385:740–743.
   PubMed Web of Science ®Google Scholar
• FROELICH-AMMON SJ, DICKINSON BA, BEVILACQUA JM, SCHULTZ SC, CECH TR: Modulation of telomerase activity by telomere DNA-binding proteins on Oxytricha. Genes Dev. (1998) 12:1504–1514.
   PubMed Web of Science ®Google Scholar
• ZAHLER AM, WILLIAMSON JR, CECH TR, PRESCOTT DM: Inhibition of telomerase by G-quartet DNA structures. Nature (1991) 350:718–720.
   PubMed Web of Science ®Google Scholar
• •This study showed inhibition of telomerase function by a DNA tetraplex and identified such structures as potential biotargets in the development of enzyme inhibitors.
   Google Scholar
• FLETCHER TM, SUN D, SALAZAR M, HURLEY LH: Effect of DNA secondary structure on human telomerase activity. Biochemistry (1998) 37:5536–5541.
   PubMed Web of Science ®Google Scholar
• HOLT SE, WRIGHT WE, SHAY JW: Multiple pathways for the regulation of telomerase activity. Eur. J. Cancer (1997) 33:761–766.
   PubMed Web of Science ®Google Scholar
• PILCH DS. PLUM GE, BRESLAUER KJ: The thermody-namics of DNA structures that contain lesions or guanine tetrads. Curr. Opin. Struct. Biol. (1995) 5:334–342.
   PubMed Web of Science ®Google Scholar
• MARATHIAS VM, BOLTON PH: Determinants of DNA quadruplex structural type: sequence and potassium binding. Biochemistry (1999) 38:4355–4364.
   PubMed Web of Science ®Google Scholar
• WOODFORD KJ, HOWELL RM, USDIN K: A novel K±-dependent DNA-synthesis arrest site in a commonly occurring sequence motif in eukaryotes. J. Biol. Chem. (1994) 269:27029–27035.
   PubMed Web of Science ®Google Scholar
• SUN D, LOPEZ-GUAJARDO CC, QUADA J, HURLEY LH, VON HOFF DD: Regulation of catalytic activity and processivity of human telomerase. Biochemistry (1999) 38:4037–4044.
   PubMed Web of Science ®Google Scholar
• HAN H, HURLEY LH, SALAZAR M: A DNA polymerase stop assay for G-quadruplex-interactive compounds. Nucleic Acids Res. (1999) 27:537–542.
   PubMed Web of Science ®Google Scholar
• JENKINS TC: Targeting multi-stranded DNA structures. Curr. Med. Chem. (1999) 6. (In Press).
   Google Scholar
• SHAFER RH: Stability and structure of model DNA triplexes and quadruplexes and their interactions with small ligands. Prog. Nucl. Acid Res. Mol. Biol. (1998) 59:55–94.
   PubMed Web of Science ®Google Scholar
• GUO Q, LU M, MARKY LA, KALLENBACH NR: Interaction of the dye ethidium bromide with DNA containing guanine repeats. Biochemistry (1992) 31:2451–2455.
   PubMed Web of Science ®Google Scholar
• SHIDA T, IKEDA N, SEKIGUCHI J: Drug binding to higher ordered DNA structures: ethidium bromide complexa-tion with parallel quadruple-stranded DNA. Nucleosides Nucleotides (1996) 15:599–605.
   Web of Science ®Google Scholar
• CHEN Q, KUNTZ ID, SHAFER RH: Spectroscopic recogni-tion of guanine dimeric hairpin quadruplexes by a carbocyanine dye. Proc. Natl. Acad. ScL USA (1996) 93:2635–2639.
   PubMed Web of Science ®Google Scholar
• SUN D, THOMPSON B, CATHERS BE et al.: Inhibition of human telomerase by a G-quadruplex-interactive compound. J. Med. Chem. (1997) 40:2113–2116.
   PubMed Web of Science ®Google Scholar
• •First report of demonstrable telomerase inhibition by a non-nucleoside agent designed to bind to the human telomeric tetraplex, showing involvement of a high-order DNA-drug complex.
   Google Scholar
• PERRY PJ, RESZKA AP, WOOD AA et al.: Human telomerase inhibition by regioisomeric disubstituted amidoanthracene-9,10-diones. J. Med. Chem. (1998) 41:4873–4884.
   PubMed Web of Science ®Google Scholar
• VENITT S, CROFTON-SLEIGH C, AGBANDJE M, JENKINS TC, NIEDLE S: Anthracene-9,10-diones as potential anticancer agents: bacterial mutation studies of amido-substituted derivatives reveal an unexpected lack of mutagenicity. J. Med. Chem. (1998) 41:3748–3752.
   PubMed Web of Science ®Google Scholar
• WHEELHOUSE RT, SUN D, HAN H, HAN FX, HURLEY LH: Cationic porphyrins as telomerase inhibitors: the interaction of tetra-(N-methyl-4-pyridy0 porphine
   Google Scholar
• ANANTHA NV, AZAM M, SHEARDY RD: Porphyrin binding to quadruplexed T4G4. Biochemistry (1998) 37:2709–2714.
   PubMed Web of Science ®Google Scholar
• ARTHANARI H, BASU S, KAWANO TL, BOLTON PH: Fluorescent dyes specific for quadruplex DNA. Nucleic Acids Res. (1998) 26:3724–3728.
   PubMed Web of Science ®Google Scholar
• HAQ I, TRENT JO, CHOWDHRY BZ, JENKINS TC: Interca-lative G-tetraplex stabilization of tetraplex DNA by a cationic porphyrin. J. Amer. Chem. Soc. (1999) 121:1768–1779.
   Web of Science ®Google Scholar
• •First systematic study of tetraplex-ligand (34) binding using calorimetric, optical and molecular modelling methods. This report highlights that solution conditions, particularly Na + or K.+ salt content, can markedly influence the stability, affinity and overall stoichiometry.
   Google Scholar
• HAN FX, SUN D, HURLEY LH: The interaction of telomerase-inhibitory porphyrins with G-quadruplex DNA. Proc. Amer. Assoc. Cancer Res. (1998) 39:2925.
   Google Scholar
• RAYMOND E, IZBICKA E, SUN D et al.: Study of telomerase inhibitors in human cancer models using a new biotinylated-primer extension assay without PCR-amplification. Proc. Amer. Assoc. Cancer Res. (1998) 39:3680.
   Google Scholar
• HAN FX, WHEELHOUSE RT, HURLEY LH: Interaction of TMPyP4 and TMPyP2 with quadruplex DNA. Structural basis for the differential effects on telomerase inhibi-tion. J. Amer. Chem. Soc. (1999) 121:3561–3570.
   Google Scholar
• IZBICKA E, WHEELHOUSE RT, RAYMOND E et al.: Effects of cationic porphyrins as G-quadruplex interactive agents in human tumor cells. Cancer Res. (1999) 59:639–644.
   PubMed Web of Science ®Google Scholar
• IZBICKA E, NISHIOKA D, LAWRENCE R et al.: Telomerase inhibitors induce chromosomal destabilization in developing sea urchin embryos. Proc. Amer. Assoc. Cancer Res. (1998) 39:2073.
   Google Scholar
• KELLAND LR, GOWAN SM, HARRISON RJ et al.: Bisubsti-tuted tricyclic chromophores as small molecule inhibitors of human telomerase: biological and modelling studies. Proc. Amer. Assoc. Cancer Res. (1999) 40:1996.
   Google Scholar
• PERRY PJ, READ MA, DAVIES RT et al.: 2,7-Disubstituted amidofluorenone derivatives as inhibitors of human telomerase. J. Med. Chem. (1999) 42:2679–2684.
   PubMed Web of Science ®Google Scholar
• PERRY PJ, GOWAN, SM, READ MA, KELLAND LR, NIEDLE S: Design, synthesis and evaluation of human telomerase inhibitors based upon a tetracyclic structural motif. AntiCancer Drug Des. (1999) 14. (In Press).
   Google Scholar
• FEDOROFF OY, SALAZAR M, HAN H et al.: NMR-based model of a telomerase-inhibiting compound bound to G-quadruplex DNA. Biochemistry (1998) 37:12367–12374.
   PubMed Web of Science ®Google Scholar
• FEDEROFF OY, SALAZAR M, KERWIN SM, HAN H, HURLEY LH: High-field NMR studies of G-quadruplex binding by a telomerase-inhibiting compound. Proc. Amer. Assoc. Cancer Res. (1998) 39:2084.
   Google Scholar
• HAQ I, LADBURY JE, CHOWDHRY BZ, JENKINS TC: Molecular anchoring of duplex and triplex DNA by disubstituted anthracene-9,10-diones: calorimetric, UV melting and competition dialysis studies. J. Amer. Chem. Soc. (1996) 118:10693–10701.
   Web of Science ®Google Scholar
• KEPPLER MD, READ MA, PERRY PJ et al.: Stabilization of DNA triple helices by a series of mono- and disubsti-tuted amidoanthraquinones. Eur. J. Biochem. (1999) 263:817–825.
   PubMedGoogle Scholar
• NAASANI I, SEIMIYA H, TSURUO T: Telomerase inhibi-tion, telomere shortening, and senescence of cancer cells by tea catechins. Biochem. Biophys. Res. Commun. (1998) 249:391–396.
   PubMed Web of Science ®Google Scholar
• •A thoroughly conducted study describing telomerase inhibi-tion in the cell-free TRAP assay combined with telomerase inhibition, telomere shortening and senescence in cell cultures at non-toxic concentrations with the inclusion of appropriate controls.
   Google Scholar
• TOGASHI KI, KAKEYA H, MORISHITA M, SONG YX, OSADA H: Inhibition of human telomerase activity by alterperylenol. Oncol Res. (1998) 10:449–453.
   PubMed Web of Science ®Google Scholar
• TABATA Y, IKEGAMI S, YAGUCHI T et al.: Diazaphilonic acid, a new azaphilone with telomerase inhibitory activity. J. Antibiotics (1999) 52:412–414.
   PubMed Web of Science ®Google Scholar
• BARE LA, TRINH L, WU S, DEVLIN JJ: Identification of a series of potent telomerase inhibitors using a time-resolved fluorescence-based assay. Drug Dev. Res. (1998) 43:109–116.
   Web of Science ®Google Scholar
• •A series of potent telomerase inhibitors are described using a high-throughput, non-radioactive assay. Good correlation with the frequently used TRAP assay is demonstrated.
   Google Scholar
• YAMORI T, TSURUO T: Screening for antitelomerase agents with the aid of COMPARE analysis. Proc. Amer. Assoc. Cancer Res. (1998) 39:3854.
   Google Scholar
• WU HL, HSU CY, LIU WH, YUNG BYM: Berberine-induced apoptosis of human leukemia HL-60 cells is associated with down-regulation of nucleo-phosmin/B23 and telomerase activity. Int. J. Cancer (1999) 81:923–929.
   PubMed Web of Science ®Google Scholar
• YAMAKUCHI M, NAKATA M, KAWAHARA K-I, KITAJIMA I, MARUYAMA I: New quinolones, ofloxacin and levofloxacin, inhibit telomerase activity in transi-tional cell carcinoma cell lines. Cancer Lett. (1997) 119:213–219.
   PubMed Web of Science ®Google Scholar
• THOMPSON MJ, BIBBY MC: The anti-tumor effect of cisplatin and the correlation between apoptosis and telomerase activity in a human testicular tumor xenograft. Proc. Amer. Assoc. Cancer Res. (1998) 39:1061.
   Google Scholar
• KU W-C, CHENG A-J, WANG T-CV: Inhibition of telomerase activity by PKC inhibitors in human nasopharyngeal cancer cells in culture. Biochem. Biophys. Res. Commun. (1997) 241:730–736.
   PubMed Web of Science ®Google Scholar
• SATO N, MIZUMOTO K, KUSUMOTO M, NIIYAMA H, MAEHARA N, OGAWA T, TANAKA M: 9-Hydroxyellipticine inhibits telomerase activity in human pancreatic cancer cells. FEBS Lett. (1998) 441:318–321.
   PubMed Web of Science ®Google Scholar
• AKIYAMA M, HORIGUCHI-YAMADA J, SAITO S et al: Cytostatic concentrations of anticancer agents do not affect telomerase activity of leukaemic cells in vitro. Eur. J. Cancer (1999) 35:309–315.
   PubMed Web of Science ®Google Scholar
• MULTANI AS, LI C, OZEN M, IMAM AS, WALLACE S, PATHAK S: Cell-killing by paclitaxel in a metastatic murine melanoma cell line is mediated by extensive telomere erosion with no decrease in telomerase activity. Oncol Reports (1999) 6:39–44.
   PubMed Web of Science ®Google Scholar
• MENTA E, PALUMBO M: Antineoplastic agents 1998. Exp. Opin. Ther. Patents (1998) 8:1627–1672.
   Web of Science ®Google Scholar